Lenalidomide Eugia

Lenalidomide, the active ingredient in Lenalidomide Eugia, is an immunomodulatory agent presented as a tablet for oral use. It treats certain blood cancers such as multiple myeloma, myelodysplastic syndromes with del(5q), mantle cell lymphoma and follicular lymphoma in adult patients.

GNH USA supplies Lenalidomide Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, clinics and research institutions worldwide.

Lenalidomide is indicated for several hematologic malignancies and works by targeting disease‑specific pathways. - Multiple Myeloma: helps control disease progression and prolong survival. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves blood counts. - Mantle Cell Lymphoma: contributes to tumor reduction in relapsed or refractory cases. - Follicular Lymphoma: used in patients with disease that has progressed after prior therapy.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Diarrhea: loose stools that may require supportive care. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia or thrombocytopenia: markedly low blood cell counts. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: liver enzyme elevations indicating liver injury.

Before initiating therapy, clinicians should assess baseline health status and monitor for specific risks. - Monitor blood counts: perform regular CBCs to detect cytopenias. - Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. - Contraindicated in pregnancy: strict contraception required for women of childbearing potential. - Adjust for renal impairment: dose modifications may be needed in reduced kidney function. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lenalidomide interacts with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may lower lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise drug levels. - NSAIDs: additive risk of gastrointestinal bleeding. - Digoxin: potential for increased serum concentrations.